Beckman Coulter, Inc.: FDA filings under this applicant name
FDA lists 280 510(k) clearances under 2 spellings of the applicant name “Beckman Coulter, Inc.” (first 1993, latest 2026), plus 5 PMA and 1 De Novo decisions, across 103 product codes in 5 review panels. Median 510(k) review time under this name: 74 days. Since 2017 the median was 135 days, against 135 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
Caduvo groups this applicant name under Danaher (Beckman Coulter, Leica Biosystems, Radiometer, Cepheid), based on public ownership records.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 2 | 188 |
| 2013 | 7 | 373 |
| 2014 | 7 | 149 |
| 2015 | 3 | 133 |
| 2016 | 3 | 164 |
| 2017 | 7 | 157 |
| 2018 | 2 | 271 |
| 2019 | 8 | 94 |
| 2020 | 6 | 90 |
| 2021 | 2 | 215 |
| 2022 | 4 | 118 |
| 2023 | 14 | 238 |
| 2024 | 19 | 90 |
| 2025 | 10 | 256 |
| 2026 | 7 | 90 |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Beckman Coulter, Inc. took a median 135 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 135 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| GKZ | Counter, Differential Cell | 28 | 28 |
| LTT | Panels, Test, Susceptibility, Antimicrobial | 12 | 12 |
| JPK | Mixture, Hematology Quality Control | 10 | 10 |
| MMI | Immunoassay Method, Troponin Subunit | 10 | 10 |
| JJX | Single (Specified) Analyte Controls (Assayed And Unassayed) | 9 | 9 |
| JIT | Calibrator, Secondary | 8 | 8 |
| LGD | Enzyme Linked Immunoabsorbent Assay, Toxoplasma Gondii | 7 | 7 |
| JIS | Calibrator, Primary | 6 | 6 |
| JJY | Multi-Analyte Controls, All Kinds (Assayed) | 6 | 6 |
| CGN | Acid, Folic, Radioimmunoassay | 5 | 5 |
Plus 93 more product codes.
Review panels
- Clinical Chemistry (116)
- Hematology (56)
- Immunology (54)
- Microbiology (37)
- Clinical Toxicology (23)
Most recent Beckman Coulter, Inc. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K262597 | Access BNP II | NBC | 2026-10-20 | 85 |
| K261109 | Access MeMed BV | QPS | 2026-10-19 | 199 |
| K262109 | Access NT-proBNP | NBC | 2026-09-21 | 90 |
| K252169 | Access BNP II | NBC | 2026-03-24 | 257 |
| K254059 | Access anti-HBc IgM | SEI | 2026-03-13 | 86 |
| K253687 | Access anti-HBc Total | SEI | 2026-02-19 | 90 |
| K251995 | Access anti-HAV IgM | LOL | 2026-01-27 | 214 |
| K250588 | Access Rubella IgG | LFX | 2025-11-17 | 263 |
| K252580 | iQ200 Series | LKM | 2025-09-10 | 26 |
| K243846 | Access anti-HAV | LOL | 2025-09-09 | 267 |
270 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| P230015 | PMA | Access HBsAg, Access HBsAg Confirmatory, Access HBsAg Calibrator, Access HBsAg QC | 2025-10-17 |
| DEN160047 | De Novo | Flow Cytometric Test System For Hematopoietic Neoplasms | 2017-06-29 |
| P090026 | PMA | ACCESS HYBRITECH P2PSA ON THE ACCESS IMMUNOASSAY SYSTEMS | 2012-06-14 |
| P980041 | PMA | ACCESS AFP IMMUNOASSAY SYSTEM | 1999-02-08 |
| P970038 | PMA | TANDEM-R FREE PSA IMMUNORADIOMETRIC ASSAY/TANDEM-MP FREE PSA IMMUNOENZYMETRIC ASSAY | 1998-03-10 |
Recalls
648 product recalls in 421 recall events; 105 initiated in the last five years. Most recent: 2026-09-21.
4 product recalls in 2 recall events filed under other recalling-firm names cite a 510(k) or PMA held under this applicant name; 3 initiated in the last five years. Most often: Beckman Coulter Biomedical GmbH (3), Assuramed (1).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
An industry sponsor named Beckman Coulter, Inc. is the lead sponsor of 4 device studies on ClinicalTrials.gov (0 active or recruiting). Most recent:
- NCT06257628: MACE CDS Software Master Enrollment Protocol (Withdrawn, started 2023-09-14)
- NCT05467449: DxFLEX 10C Clinical Study (Completed, started 2022-04-12)
- NCT04804306: Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC (Completed, started 2021-09-05)
- NCT04816630: Feasibility Study of Hematology Parameters in COVID-19 Disease (Completed, started 2020-12-21)
Parent company SEC filings
DANAHER CORP /DE/ (DHR): EDGAR filings, CIK 313616. Caduvo groups Beckman Coulter, Inc. under Danaher (Beckman Coulter, Leica Biosystems, Radiometer, Cepheid); the parent's SEC registrant is entered by hand for the group, not matched by name.
FDA spellings included
FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:
- Beckman Coulter, Inc. (278)
- Beckman Coulter (8)
Other FDA applicant names starting with the same word
FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.
- Beckman Instruments, Inc. (281 510(k)s)
- Beckman-Diagnostic Systems Group (11 510(k)s)
- Beckman Coulter Ireland, Inc. (7 510(k)s)
- Beckman (6 510(k)s)
- Beckman Coulter Laboratory Systems (Suzhou) Co., Ltd. (2 510(k)s)
- Beckman Analytical and Biotechnology Development (1 510(k)s)
- Beckman Coulter Biomedical GmbH (1 510(k)s)
- Beckman Coulter Cellular (1 510(k)s)
Frequently asked questions
How many FDA 510(k) clearances are listed under Beckman Coulter, Inc.?
FDA lists 280 510(k) clearances under 2 spellings of the applicant name “Beckman Coulter, Inc.” (first 1993, latest 2026), plus 5 PMA and 1 De Novo decisions, across 103 product codes in 5 review panels. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Beckman Coulter, Inc.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Beckman Coulter, Inc. is 74 days. Since 2017: 135 days, versus 135 days for all cleared 510(k)s in the same product codes.
Which FDA product codes appear under Beckman Coulter, Inc.?
The most frequent FDA product codes under this applicant name are GKZ (Counter, Differential Cell, 28); LTT (Panels, Test, Susceptibility, Antimicrobial, 12); JPK (Mixture, Hematology Quality Control, 10).
Next steps
- See all 280 Beckman Coulter, Inc. clearances with predicates and recalls
- Run predicate analysis for product code GKZ, Beckman Coulter, Inc.'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.